Red Cell Transfusion Threshold Guide
Pick a clinical setting and see the haemoglobin trigger each authority actually states for it — AABB 2023, the 2025 AABB myocardial infarction guideline, ACG 2021, NICE NG24 and the Surviving Sepsis Campaign — with the randomised trial each figure rests on. Where two societies genuinely disagree, both numbers are shown attributed rather than averaged, and settings every document excludes return no number at all. There is no single universal trigger and this page never prints one.
Each of these is a situation a guideline explicitly writes itself out of, or one where a guideline adds a separate statement. Only the boxes that matter for the chosen setting are shown.
No haemoglobin figure on this page originates here. Every trigger, every strength of recommendation and every certainty rating is transcribed from one of five published documents, each read from primary text rather than from a summary of it, and each named on the card that carries its number. The table below lists all five in full, with the identifier needed to open the source and check the wording against what this tool prints.
| Document | Citation and official source | Method | As of |
|---|---|---|---|
| AABB 2023 Association for the Advancement of Blood & Biotherapies, with the International Society of Blood Transfusion, the International Collaboration for Transfusion Medicine Guidelines, the Society of Critical Care Medicine, the European Blood Alliance and the Society for the Advancement of Patient Blood Management | Carson JL, Stanworth SJ, Guyatt G, et al. Red Blood Cell Transfusion: 2023 AABB International Guidelines. JAMA. 2023;330(19):1892-1902. Official source DOI 10.1001/jama.2023.12914 · PMID 37824153 | GRADE, 45 randomised controlled trials with 20,599 adult participants and 7 trials with 2,730 paediatric participants | 2023-11-21 |
| AABB 2025 (AMI) Association for the Advancement of Blood & Biotherapies international panel | Pagano MB, Stanworth SJ, Dennis J, et al. Red Cell Transfusion in Acute Myocardial Infarction: AABB International Clinical Practice Guidelines. Ann Intern Med. 2025;178(10):1469-1477. Official source DOI 10.7326/ANNALS-25-00706 · PMID 40825204 | GRADE, meta-analysis of randomised trials of restrictive versus liberal strategies in acute myocardial infarction using Cochrane methods | 2025-08-19 |
| ACG 2021 (UGIB) American College of Gastroenterology | Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding. Am J Gastroenterol. 2021;116(5):899-917. Official source DOI 10.14309/ajg.0000000000001245 · PMID 33929377 | GRADE, systematic reviews of predefined clinical questions | 2021-05 |
| NICE NG24 National Institute for Health and Care Excellence (England) | Blood transfusion. NICE guideline NG24. National Institute for Health and Care Excellence, published 18 November 2015. Official source NICE guideline NG24 | NICE guideline development; recommendations are worded ‘use’ or ‘consider’ rather than GRADE-rated in the published recommendation text | 2015-11-18 |
| Surviving Sepsis 2026 Society of Critical Care Medicine and European Society of Intensive Care Medicine | Prescott HC, Antonelli M, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026. Crit Care Med. 2026;54(4):725-812. Official source DOI 10.1097/CCM.0000000000007075 · PMID 41869847 | GRADE | 2026-03 |
The trial evidence underneath. Nine randomised controlled trials sit behind those recommendations, and the tool opens only the ones that enrolled the population selected above: TRICC (1999), TRISS (2014), Villanueva 2013 (2013), TRIGGER (2015), TRICS III (2017), FOCUS (2011), MINT (2023), REALITY (2021), TRIPICU (2007). Each trial panel reproduces that trial’s own restrictive and liberal arm definitions, its primary outcome as the authors defined it, the published result with its confidence interval, and the authors’ own concluding sentence. Nothing is restated in friendlier words.
One figure here is a convention rather than a published value. The conversion between the two unit systems is definitional: one gram per decilitre is exactly ten grams per litre. Every threshold is therefore shown in both units with no rounding in either direction, because United Kingdom and European documents state these numbers in g/L and United States documents state them in g/dL, and a reader comparing NICE with AABB is otherwise comparing numbers that look ten times apart.
Reference data build date. The underlying data file was built 2026-08-01 and carries a re-verification date of 2027-02-01. Guidelines are revised; a reader using this page after that date should confirm each figure against the linked source.
The tool reports position, not permission. Entering a haemoglobin does not produce a recommendation to transfuse or to withhold. It produces an arithmetic statement — this value is 0.4 g/dL below the figure that source states — next to the sentence the source actually wrote. The distance is the useful part: a value 2 g/dL under every threshold on screen is a different conversation from one sitting 0.1 g/dL under a single conditional recommendation.
A trigger and a target are not the same number. Most of these documents state only the first. NICE NG24 is the only source implemented here that also gives a post-transfusion haemoglobin target — 70 to 90 g/L in general, and 80 to 100 g/L in acute coronary syndrome — which is why target ranges appear on NICE cards and nowhere else. The absence of a target on the other cards is not an oversight; those panels did not state one.
Strong and conditional carry different weight. A strong recommendation means the panel judged that most well-informed patients would want the recommended course. A conditional or weak recommendation means the panel judged that choices would reasonably differ. Only three statements on this page are strong: AABB Recommendation 1 for the stable hospitalised adult, AABB Recommendation 3 for the critically ill child, and the Surviving Sepsis Campaign directional recommendation. The acute myocardial infarction, haematology and oncology, paediatric congenital heart disease and upper gastrointestinal bleeding recommendations are all conditional, and the certainty rating printed beneath each card says how much trial evidence stands behind it.
Exactly at the number is genuinely ambiguous. Some documents say “less than 7 g/dL” and others say “a threshold of 7 g/dL”. At exactly 7.0 those are not the same statement, and the tool says so rather than resolving it. The range in which any of these figures is meaningful is roughly 6 to 10 g/dL; outside it the question is no longer which threshold applies.
The number moves with the population, not with the reading. Changing the setting changes the trial evidence, and the whole reason this page exists is that the two most recent documents point in opposite directions: 7 g/dL for a stable inpatient, 10 g/dL after a myocardial infarction. Averaging those would misrepresent both, so no single universal trigger is printed anywhere on this page.
Consider an inpatient in their seventies admitted with melaena, circulation stable after initial fluids, no chest pain and no known coronary disease, whose haemoglobin comes back at 6.8 g/dL. Selecting Acute upper gastrointestinal bleeding and entering 6.8 returns the ACG 2021 statement — a conditional recommendation, low-quality evidence, threshold 7 g/dL — and marks the entered value as 0.2 g/dL below the figure that source states. Alongside it sits AABB Recommendation 1 at the same 7 g/dL, strong and moderate certainty, with a note that the AABB guideline never names upper gastrointestinal bleeding as a subgroup at all.
The Villanueva trial panel opens underneath and is where the 7 g/dL came from: 921 patients, restrictive arm transfused below 7 g/dL, liberal arm below 9 g/dL, six-week survival 95 versus 91 per cent (hazard ratio for death 0.55, 95% CI 0.33 to 0.92, P = 0.02), further bleeding 10 versus 16 per cent, and 51 per cent of the restrictive arm transfused not at all.
Now consider the same reader ticking Hypotensive at presentation. The cards do not change, but the ACG’s own narrative appears beneath them with no separate figure attached: haemoglobin in a hypotensive patient will be lower after fluid resuscitation even without further bleeding, so the panel agreed it is reasonable to transfuse before 7 g/dL is reached. Ticking Major or exsanguinating haemorrhage instead removes every number from the screen, because the trial that produced the 7 g/dL figure excluded exactly those patients and NICE writes major haemorrhage out of its restrictive rule in the recommendation text itself. A calculator that kept printing 7 g/dL there would be quoting a study of a different patient.
A calculator is only trustworthy if it names the cases it should not be used for. These are the ones for this page, and in most of them the tool actively declines to display a figure rather than displaying a misleading one.
And one that applies everywhere. A haemoglobin concentration is not the decision. The AABB panel says as much in its own concluding text: optimal transfusion practice relies not only on threshold concentrations but on the patient’s symptoms, signs, comorbid conditions, rate of bleeding, values and preferences. This page shows where a number sits against published guidance. It does not know the patient.